- Medicinal Chemistry
- Process Research
- Sourcing of raw materials, API’s and intermediates, globally
- Peptides, Oligonucleotides, Carbohydrates and Synthetic Lipids
- Handling of DEA controlled substances
- Impurity and metabolite characterization
- Sourcing of reference standards
- Route Scouting
- Free Screening, SFC separations under cGMP
- Stability studies
- Patent and Intellectual property challenges
- Phase 1 to Commercial API Manufacturing
- In-Vitro ADME toxicology
- Pre-formulation work, salt and polymorph screens
CEO at Drug Discovery Alliances
Deborah has decades of business development experience marketing contract services, drug licensing and new technologies to the pharmaceutical industry. She founded Drug Discovery Alliances, Inc. in 2001 to connect pharmaceutical and biotech companies with top industry contractors who facilitate and speed projects. Deborah earned a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill and has worked as an organic chemist for Rhone Poulenc. She subsequently worked for Accelyrs and MDL, marketing molecular modeling technologies and databases including Beilstein and Crossfire to the pharmaceutical industry.
Latest posts by Deborah Minor (see all)
- Drug Discovery Alliances at CPHI Barcelona 2023! - October 6, 2023
- Enhancing Resilience in Pharmaceutical Supply Chains with Drug Discovery Alliances - September 4, 2023
- Igniting Innovation through Supplier Diversity: Collaborate with Drug Discovery Alliances at Chemoutsourcing 2023! - August 14, 2023